These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 22803517)
1. Gene therapy as a vaccine for HIV-1. Berkhout B; Sanders RW Expert Opin Biol Ther; 2012 Oct; 12(10):1315-21. PubMed ID: 22803517 [TBL] [Abstract][Full Text] [Related]
2. Biological considerations in the development of a human immunodeficiency virus vaccine. Nathanson N; Mathieson BJ J Infect Dis; 2000 Aug; 182(2):579-89. PubMed ID: 10915092 [TBL] [Abstract][Full Text] [Related]
3. Improved outlook on HIV-1 prevention and vaccine development. Vasan S; Michael NL Expert Opin Biol Ther; 2012 Aug; 12(8):983-94. PubMed ID: 22583109 [TBL] [Abstract][Full Text] [Related]
4. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. Ramakrishna L; Anand KK; Mohankumar KM; Ranga U J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713 [TBL] [Abstract][Full Text] [Related]
5. Challenges in the development of an effective HIV vaccine: current approaches and future directions. Klein E; Ho RJ Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285 [TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Girard MP; Osmanov S; Assossou OM; Kieny MP Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747 [TBL] [Abstract][Full Text] [Related]
7. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886 [TBL] [Abstract][Full Text] [Related]
8. AIDS vaccine development: the long and winding road. Garber DA; Feinberg MB AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562 [TBL] [Abstract][Full Text] [Related]
9. [Vaccines against HIV]. Holm-Hansen C Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118 [TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
11. Virus-like particles: designing an effective AIDS vaccine. Young KR; McBurney SP; Karkhanis LU; Ross TM Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718 [TBL] [Abstract][Full Text] [Related]
12. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells. Wang B; Merva M; Dang K; Ugen KE; Boyer J; Williams WV; Weiner DB AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S35-41. PubMed ID: 7865331 [TBL] [Abstract][Full Text] [Related]
13. Nano-vaccines for gene delivery against HIV-1 infection. Li S; Zhang MY; Yuan J; Zhang YX Expert Rev Vaccines; 2023; 22(1):315-326. PubMed ID: 36945780 [TBL] [Abstract][Full Text] [Related]
15. Rethinking globally relevant vaccine strategies to human immunodeficiency virus type-1. Gray CM; Puren AJ Arch Immunol Ther Exp (Warsz); 2000; 48(4):235-41. PubMed ID: 11059639 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834 [TBL] [Abstract][Full Text] [Related]
17. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502 [TBL] [Abstract][Full Text] [Related]
18. Virus-like particles as HIV-1 vaccines. Doan LX; Li M; Chen C; Yao Q Rev Med Virol; 2005; 15(2):75-88. PubMed ID: 15484204 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens. Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]